Cancer therapy resistance remains a formidable barrier in oncology, thwarting curative attempts and driving relapse. Traditional explanations have centered on genetic mutations and epigenetic modifications; however, the complex web of cellular metabolism is increasingly recognized as a critical influence in this landscape. The study harnesses advanced biochemical tools to demonstrate how lactate, a metabolic byproduct historically viewed as a waste molecule, plays an active role in modifying proteins through a process named lactylation. This modification alters protein function, co-opting cellular pathways to foster resistance.

Mechanistically, lactylation involves the covalent attachment of lactyl groups to lysine residues on histone and non-histone proteins, fundamentally altering their spatial conformation and interaction networks. Such modifications influence chromatin architecture and gene expression, reprogramming cancer cells towards phenotypes that withstand cytotoxic stress. The authors elucidate how elevated glycolytic flux—common in cancer cells exhibiting the Warburg effect—leads to increased intracellular lactate concentrations, which in turn fuel this modification, establishing a direct metabolic-genetic link.

Key to these findings is the identification of critical proteins involved in DNA repair, apoptosis regulation, and drug metabolism that are subject to lactylation. This implicates the modification as a master regulator in cellular decisions during chemotherapy or radiotherapy. Notably, the study deploys mass spectrometry-based proteomics combined with chromatin immunoprecipitation assays to map lactylation sites and assess functional outcomes. These technologies have revealed dynamic patterns of lactylation coinciding with exposure to therapeutic agents.

The implications for clinical oncology are profound. By interfering with the enzymes responsible for adding or removing lactyl groups—termed lactyltransferases and delactylases—there is potential to sensitize resistant tumors. The research discusses candidate enzymes that mediate lactylation, highlighting their roles as emerging drug targets. Furthermore, integrating lactylation inhibitors with existing chemotherapeutics could disrupt cancer cells’ metabolic adaptation, amplifying therapeutic efficacy.

Beyond direct enzyme targeting, the study also raises the possibility of modulating metabolic pathways upstream to curtail lactate production, thereby indirectly impairing lactylation. Strategies such as glycolysis inhibition, or manipulation of lactate transporters, may recalibrate the cellular milieu to reduce lactylation-mediated resistance. This metabolic intervention paradigm complements genetic and epigenetic therapies, offering a holistic approach against therapy-resistant cancers.

The authors delve into the epigenetic dimension of protein lactylation, demonstrating how histone lactylation dynamically controls the transcription of genes involved in cellular stress responses. Such epigenetic reprogramming equips cancer cells with a rapid, reversible mechanism to evade therapeutic pressures. This plasticity challenges conventional views on permanent genetic resistance, positioning lactylation as a flexible metabolic-epigenetic interface.

Intriguingly, the study also examines the interplay between lactylation and other post-translational modifications, including acetylation and methylation, revealing a complex crosstalk that fine-tunes protein function. This multilayered regulation underscores the sophistication of cancer cell adaptation, highlighting the need for combinatorial therapeutic strategies that target multiple modification pathways simultaneously.

Experimental validations extend across various cancer models, including solid tumors and hematologic malignancies, underscoring the broad relevance of lactylation in oncogenesis. This universality suggests that targeting lactylation could become a foundational element in the oncology toolkit, applicable across diverse cancer types and stages, from initial diagnosis through metastatic progression.

Moreover, the study invites reconsideration of the metabolic landscape within tumor microenvironments. By elevating extracellular lactate, resistant cancer cells might modulate immune cell function and stromal interactions through lactylation effects, potentially contributing to immune evasion and therapy failure. This insight bridges tumor metabolism and immunotherapy, hinting at synergistic therapeutic opportunities.

In discussing future directions, the authors emphasize the necessity for comprehensive in vivo studies to validate lactylation inhibitors’ safety and efficacy. Additionally, development of selective biomarkers indicative of lactylation status could revolutionize precision oncology, enabling real-time monitoring of therapeutic resistance and informing adaptive treatment strategies.

This research marks a paradigm shift, asserting protein lactylation as a metabolic signaling nexus empowering cancers to subvert therapeutic cells death. It challenges the long-standing waste product stereotype assigned to lactate, recasting it as a critical protagonist in cancer biology. Understanding and manipulating this metabolic signature may finally tip the scale in favor of successful, durable cancer therapies.

In summary, D’amico and colleagues deliver compelling evidence that protein lactylation orchestrates a sophisticated metabolic strategy exploited by cancer cells to resist therapy. This discovery enriches our comprehension of cancer cell plasticity and highlights new metabolic-epigenetic targets. The path forward envisions integrating lactylation modulation into existing treatment regimens, forging a multifaceted offensive against one of medicine’s most daunting challenges.

As the scientific community digests these findings, a new dialogue emerges around tumor metabolism’s role in therapy resistance, demanding innovative research and clinical trials. The potential for translating these insights into transformative cancer treatments portends a hopeful horizon where therapeutic resistance can be not only understood but overcome.

Subject of Research: Protein lactylation as a metabolic signal driving cancer therapy resistance

Article Title: Protein lactylation: a metabolic signal driving cancer therapy resistance

Article References:
D’amico, S., Giovannini, S., Melino, G. et al. Protein lactylation: a metabolic signal driving cancer therapy resistance. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03050-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03050-w

Discovered only in 2019, lysine lactylation initially gained recognition as a histone modification linked to epigenetic regulation. Histones, the protein spools around which DNA wraps, are subject to various chemical modifications that dynamically alter chromatin structure and transcriptional activity. Kla on key histone sites such as H3K18la, H3K23la, and H4K12la has been implicated in crucial biological processes including early embryogenesis, immune modulation, metabolic reprogramming in cancer, and tumor progression. However, the new review reveals that Kla’s scope extends far beyond chromatin, modifying a wide spectrum of non-histone proteins, thereby orchestrating multifaceted cellular functions.

One of the major leaps this review achieves is integrating mechanistic insights about the enzymes involved in Kla. The authors present updated information on ‘writers’ that install Kla marks, ‘erasers’ that remove them, and ‘readers’ that recognize lactylated lysines, drawing parallels yet highlighting distinctions between histone and non-histone substrates. Intriguingly, the modification can arise through enzymatic pathways involving L-lactyl-CoA synthetases like ACSS2 and GTPSCS, or via non-enzymatic methods in metabolically active environments. This dual mode of Kla regulation underscores its adaptability as a metabolic sensor and effector.

Non-histone protein lactylation is emerging as a powerful regulator of cellular processes far removed from canonical epigenetics. For instance, lactylation of Vps34 plays a pivotal role in autophagy, a fundamental cellular housekeeping pathway. Similarly, Tau-Kla influences ferroptosis, a form of regulated cell death linked to neurodegenerative diseases. Immune signaling pathways are also modulated via lactylation of proteins such as RIG-I and BCAP, implicating Kla in antiviral defense and inflammatory responses. This broadened landscape reveals Kla as a nexus connecting metabolic states to diverse cell functions.

The review also outlines the functional and pathological relevance of Kla in cancer biology. Histone Kla promotes tumor angiogenesis through epigenetic activation of key players like HIF1-ɑ and Vegf, aiding tumor vascularization. Beyond histones, non-histone lactylation of proteins such as YY1 and Sema3A influences the tumor microenvironment by regulating FGF2 and HIF1-ɑ, respectively. Moreover, Kla on enzymes like LDHA modulates glycolytic flux, directly impacting cancer cell proliferation. These insights open new avenues for targeting metabolic-epigenetic crosstalk in oncology.

Importantly, the authors shed light on Kla’s integral role in tumor immunity. Histone Kla can modulate T cell responses, shaping immune surveillance. Meanwhile, lactylation of ALKBH5, CBX3, and the innate immune sensor RIG-I fine-tunes expression of immune checkpoint molecules and inflammation regulators like IFN-R, CD47, and NLRP3. This highlights Kla’s potential as a lever for immunotherapeutic strategies, a rapidly evolving frontier in cancer treatment.

Advancing technical capabilities have propelled Kla research to new heights. The review emphasizes cutting-edge detection techniques such as CUT&Tag and tandem mass spectrometry that afford site-specific mapping of lactylation marks with unprecedented resolution. These innovations enable precise dissection of Kla landscapes in physiological and pathological contexts, facilitating the development of Kla-targeted diagnostics and therapeutics.

Moreover, the review situates Kla within a broader pathological spectrum, linking it to cardiovascular disease, sepsis, and neurodegeneration. For instance, the association of histone H3K18la with macrophage polarization and pulmonary hypertension suggests Kla’s involvement in inflammatory and vascular disorders. This expansive disease relevance positions Kla as a critical node in metabolic signaling with far-reaching clinical implications.

Notably, Prof. Du and Dr. Peng emphasize that Kla represents an underappreciated epigenetic and post-translational modification axis. Their comprehensive synthesis underscores the need to bridge previous histone-centric approaches with emerging evidence of non-histone protein lactylation. Understanding this axis could illuminate key mechanisms whereby metabolic dysregulation rewires cellular behavior, advancing both fundamental biology and translational medicine.

Ultimately, this authoritative review represents a call to action for the scientific community. By systematically integrating knowledge of histone and non-histone lactylation, the authors unveil promising therapeutic targets across cancer, immunity, and metabolic disorders. The Kla axis is poised to become a vibrant area of research, revolutionizing our grasp of how metabolic cues sculpt the cellular proteome and epigenome to influence health and disease.

With metabolism at the helm of cellular regulation, lysine lactylation emerges as a master regulator, deftly linking metabolic environments to intricate biological outcomes. As Kla research gains momentum, its clinical translation offers hope for new interventions tailored to the metabolic landscapes of complex diseases. This review by Du and Peng not only synthesizes the current state of the field but establishes a roadmap for the future, heralding a new era in molecular biomedicine where metabolism and epigenetics converge through lactylation.

Subject of Research: Lysine lactylation (Kla) in histone and non-histone proteins: molecular mechanisms, biological functions, and therapeutic potential

Article Title: Histone and non-histone lactylation: molecular mechanisms, biological functions, diseases, and therapeutic targets

News Publication Date: 9-Jun-2025

Web References: DOI: 10.1186/s43556-025-00275-6

Image Credits: Juan Du

Within the context of tumorigenesis, PTMs mediated by metabolic substrates—hitherto celebrated examples focusing on histone acetylation—have pivoted attention toward a broader spectrum of ‘acyl’ modifications. These metabolite-derived PTMs are increasingly recognized as pivotal determinants of cancer cell behavior, influencing survival, proliferation, metastasis, and drug resistance. Such modifications fine-tune not only the function of non-histone proteins through direct alteration of enzymatic and structural properties but also modulate chromatin architecture and gene expression patterns by modifying histones, thereby reshaping transcriptional landscapes central to oncogenesis.

Driven by the altered metabolic milieu typical of cancer cells, aberrant levels of metabolites fuel a cascade of unique PTMs. This metabolic dysregulation serves as both a consequence and driver of tumor progression, with metabolic byproducts acting as donors for covalent modifications that can activate oncogenic pathways or suppress tumor suppressor functions. Recent advances have delineated a variety of novel acyl PTMs, such as lactylation, crotonylation, and butyrylation, all contributing distinct regulatory cues. These modifications collectively rewire cellular signaling and epigenetic frameworks, exemplifying a sophisticated interplay between metabolism and protein function that underscores the multifaceted progression of malignancies.

Crucial to the investigation of metabolite-driven PTMs is the mastery of analytical technologies capable of precise and comprehensive detection. Traditional platforms like liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) have established themselves as core methodologies to characterize metabolite profiles within tumor cells. However, challenges persist in detecting metabolites exhibiting strong polarity, structural isomerism, or inherently low ionization efficiencies, thereby hindering a holistic capture of the PTM landscape. To surmount these obstacles, cutting-edge chromatography techniques employing chemical derivatization strategies have emerged. These approaches chemically stabilize target metabolites by connecting them to derivatization reagents, enhancing their ionization potential and chromatographic behavior, thus enabling more sensitive and accurate profiling essential for unraveling PTM-mediated mechanisms in cancer.

The therapeutic implications of targeting metabolite-mediated PTMs in oncology are enticing and increasingly tangible. By focusing on key enzymes involved in the biosynthesis, installation, or removal of aberrant PTMs, researchers aim to thwart the pathological signaling cascades that underpin tumor growth and resistance. For instance, compelling evidence highlights lactylation of the DNA repair protein NBS1 as a driver of chemoresistance through facilitation of homologous recombination. Experimental interventions using LDHA inhibitors, such as stripentol, or genetic ablation of LDHA substantially reduce NBS1 lactylation, bolstering chemotherapy sensitivity. This exemplifies how precision targeting of metabolic-epigenetic crosstalk can potentiate existing cancer therapies and overcome refractory disease states.

Beyond pharmacologic inhibition, innovative molecular tools including cell-penetrating peptides and small molecule antagonists offer promising avenues to selectively inhibit pathological PTMs on target proteins. These approaches hold potential not only to modulate cancer cell phenotypes but also to circumvent the off-target toxicities prevalent in systemic enzyme inhibition. The development of these next-generation modulators is grounded in a deepening mechanistic understanding of PTM networks and their cellular consequences, heralding a new era of metabolic-epigenetic interventions tailored to tumor-specific vulnerabilities.

Equally compelling is the recognition that diet and metabolic homeostasis profoundly influence tumor biology by modulating PTMs. Nutritional interventions have emerged as ancillary strategies capable of disrupting acyl modifications conducive to malignancy. For example, dietary restriction of palmitic acid (PA) has been shown to suppress palmitoylation of the oncogenic kinase AKT, effectively impeding liver cancer progression in experimental models. This insight underscores the broader concept that lifestyle and metabolic equilibrium can intersect with molecular oncogenesis via the regulation of PTMs, presenting opportunities for preventive and adjunctive cancer management.

Despite the rapid strides in characterizing acyl PTMs, significant challenges remain. One fundamental obstacle is the low stoichiometry of these modifications, where only a minor subset of the proteome is modified at any given time, presenting difficulties for detection and quantification. Such scarcity demands highly sensitive and robust proteomics workflows to capture these elusive yet functionally critical modifications. Moreover, the diversity of PTMs is continuously expanding, with newly described modifications like alkylation and vitcylation broadening the functional repertoire and complexity of protein regulation in cancer.

Another layer of intricacy arises from PTM crosstalk—where multiple modifications coexist on a single protein and influence each other’s installation or removal. This interdependency creates a regulatory web that governs protein function in a context-dependent manner, complicating mechanistic dissection and therapeutic targeting. To date, most research has focused on isolated PTMs on individual proteins, but future studies must integrate combinatorial PTM landscapes to fully elucidate their biological and pathological significance.

Translating these molecular insights into clinically effective therapies presents its own hurdles. Enzymes responsible for PTM installation or erasure, such as acyltransferases and deacylases, are often challenging drug targets due to their broad substrate specificity and potential systemic side effects. Despite this, preclinical innovations like the lactyl-resistant knock-in mouse model developed to activate innate immunity demonstrate the promise of genetically informed PTM targeting strategies. However, the clinical translatability and generalizability of such interventions require thorough validation and optimization to ensure safety, efficacy, and applicability across diverse tumor types.

Looking forward, the convergence of metabolomics, proteomics, and epigenetic research holds immense promise for revealing previously unrecognized mechanisms by which metabolites drive tumor progression via PTMs. Advanced techniques and integrative analyses will refine our understanding of the metabolic-epigenetic interface, paving the way for novel biomarkers and therapeutic targets. Harnessing this knowledge could revolutionize cancer diagnosis, enable precision therapeutics, and inform preventative strategies grounded in metabolic modulation.

Ultimately, the burgeoning field of metabolite-mediated PTMs invites a paradigm shift in oncology, expanding the frontiers beyond genetic and epigenetic mutations to encompass the dynamic chemical modifications that define cellular identity and fate. By deciphering the language of acyl modifications, scientists are opening new avenues toward conquering cancer’s complexity, ushering in a future where tumor metabolism is not merely a hallmark of disease but a linchpin for its control and eradication.

Subject of Research: Metabolite-mediated post-translational modifications in cancer cells and their implications for tumor progression and therapy.

Article Title: Acyl post-translational modification of proteins by metabolites in cancer cells.

Article References:

Wang, X., Guo, Y., Fu, Y. et al. Acyl post-translational modification of proteins by metabolites in cancer cells.
Cell Death Discov. 11, 247 (2025). https://doi.org/10.1038/s41420-025-02535-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02535-4